ERBB2 and cancer: ADCs constitute a promising treatment avenue across various cancer types, and remain an important focus of ongoing research and development.[13] T-DXd is an ADC composed of a humanized monoclonal anti-HER2 antibody, cleavable tetrapeptide-based linker, and potent topoisomerase I inhibitor.